Icosavax, Inc.
ICVXNASDAQHealthcare
$15.31
$-0.14(-0.91%)
Market Cap$769036610
P/E Ratio—
52W High$16.105
52W Low$4.75
Icosavax, Inc.（ICVX）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ICVX · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $0.58M | $7.80M | $1.62M | $0.00M |
| Cost of Revenue | $1.84M | $0.08M | $17.67M | $4.16M |
| Gross Profit | ($1.26M) | $7.72M | ($16.05M) | ($4.16M) |
| Gross Margin %(computed) | -216.67% | 98.95% | -993.25% | — |
| Operating Expenses | ||||
| R&D Expenses | $65.41M | $38.78M | $17.67M | $4.16M |
| G&A Expenses | $30.23M | $34.89M | $2.66M | $1.24M |
| Total Operating Expenses | $95.06M | $65.86M | $18.71M | $5.40M |
| Operating Income | ($95.06M) | ($65.86M) | ($18.71M) | ($5.40M) |
| Operating Margin %(computed) | — | -844.16% | — | — |
| Interest Income | $0.00M | $0.15M | $0.33M | $0.10M |
| Interest Expense | $0.00M | $0.15M | $0.33M | $0.00M |
| Income Before Tax | ($91.76M) | ($66.97M) | ($18.85M) | ($5.30M) |
| Income Tax Expense | ($3.30M) | $1.03M | $0.33M | ($0.10M) |
| Net Income | ($88.46M) | ($68.00M) | ($19.18M) | ($5.20M) |
| Net Margin %(computed) | — | -871.56% | — | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-2.23 | $-3.78 | $-6.67 | $-0.51 |
| Wtd Avg Shares | 39.73M | 17.97M | 2.88M | 10.24M |
| EBITDA | ($94.20M) | ($64.90M) | ($18.52M) | ($5.40M) |
| EBITDA Margin %(computed) | — | -831.86% | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Icosavax, Inc.
关于Icosavax, Inc.（ICVX）损益表
Icosavax, Inc.（ICVX）损益表数据来源于SEC Form 10-K及10-Q申报文件。2022财年，ICVX实现营收$0.00B，毛利润($0.00B)（毛利率-216.67%），净利润($0.09B)（净利率-15198.97%）。
常见问题
ICVX · 4 问Icosavax, Inc.（ICVX）2022财年营收为$0.00B，同比down92.5%。
ICVX revenueICVX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09